Page last updated: 2024-12-08

gadolinium oxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

gadolinium oxide: RN given refers to cpd with MF of Gd2-O3 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID159427
MeSH IDM0096617

Synonyms (27)

Synonym
11129-31-0
gadolinium oxide
gadolinium oxide (gd2o3)
gadolinium trioxide
gadolinia
digadolinium trioxide
einecs 235-060-9
gadolinium sesquioxide
gadolinium(3+) oxide
gadolinium(iii) oxide
5480d0nhlj ,
unii-5480d0nhlj
gadolinium oxide [who-dd]
gadolinium oxide powder, 99.9+% (reo) nano
gadolinium oxide powder, 99.9% (reo) nano
gadolinium(iii)oxide
CMIHHWBVHJVIGI-UHFFFAOYSA-N
FT-0696791
gadolinium(iii) oxide, reacton?
mfcd00011026
SY010046
DTXSID00912093
gadolinium oxide (2/3)
Q419919
AMY22279
A921982
gadolinium(3+);oxygen(2-)

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"It was to explore the clinical efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) targeted drugs combined with hyaluronic acid-gadolinium sesquioxide-nanoparticles (HA-Gd2O3-NPs) in non-small cell lung cancer (NSCLC)."( Clinical practice of epidermal growth factor receptor-tyrosine kinase inhibitor targeted drugs combined with gadolinium oxide nanoparticles in the treatment of non-small cell lung cancer.
Jin, T; Wang, L; Xiao, X; Zhao, E; Zhou, X, 2022
)
0.93
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (171)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (1.75)18.7374
1990's1 (0.58)18.2507
2000's31 (18.13)29.6817
2010's113 (66.08)24.3611
2020's23 (13.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.83 (24.57)
Research Supply Index5.19 (2.92)
Research Growth Index6.51 (4.65)
Search Engine Demand Index63.62 (26.88)
Search Engine Supply Index2.03 (0.95)

This Compound (43.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.56%)5.53%
Reviews2 (1.12%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other175 (98.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]